Vaccine Update: Issue 258, February 2017
Total Page:16
File Type:pdf, Size:1020Kb
Load more
Recommended publications
-
The Hexavalent Dtap/IPV/Hib/Hepb Combination Vaccine: Information for Healthcare Practitioners About the Neonatal Selective
The hexavalent DTaP/IPV/Hib/HepB combination vaccine Information for healthcare practitioners about the neonatal selective immunisation programme for babies at risk of hepatitis B The Hexavalent DTaP/IPV/Hib/HepB combination vaccine: Information for Healthcare Practitioners (selective programme) About Public Health England Public Health England exists to protect and improve the nation’s health and wellbeing, and reduce health inequalities. We do this through world-leading science, research, knowledge and intelligence, advocacy, partnerships and the delivery of specialist public health services. We are an executive agency of the Department of Health and Social Care, and a distinct delivery organisation with operational autonomy. We provide government, local government, the NHS, Parliament, industry and the public with evidence-based professional, scientific and delivery expertise and support. Public Health England Wellington House 133-155 Waterloo Road London SE1 8UG Tel: 020 7654 8000 www.gov.uk/phe Twitter: @PHE_uk Facebook: www.facebook.com/PublicHealthEngland For queries relating to this document, please contact: [email protected] © Crown copyright 2020 You may re-use this information (excluding logos) free of charge in any format or medium, under the terms of the Open Government Licence v3.0. To view this licence, visit OGL. Where we have identified any third party copyright information you will need to obtain permission from the copyright holders concerned. First published November 2017 This updated version published February -
Even Partial COVID-19 Vaccination Protects Nursing Home Residents
News & Analysis News From the Centers for Disease Control and Prevention Even Partial COVID-19 Vaccination lence of underlying medical conditions,” the Protects Nursing Home Residents authors wrote. A CDC analysis has shown that a single dose Waning COVID-19 cases as more resi- of the Pfizer-BioNTech COVID-19 vaccine dents and staff received second vaccina- protected medically vulnerable nursing tions made it impossible to assess vaccine ef- home residents as well as it did general adult fectiveness after 2 doses. Evidence from populations that were evaluated in other ef- previous studies demonstrated greater pro- ficacy and effectiveness studies. tection among older adults after a second The analysis helps fill a data gap about dose, suggesting that completing the 2-dose vaccine effectiveness in this high-risk regimen may be particularly important to group—generally older, frail adults with un- protect long-term care facility residents, the derlying health conditions—who were left authors suggested. out of COVID-19 vaccine trials. Excluding older adults from the trials raised questions Vaccine Dramatically Reduces HPV about how well nursing home residents Infection Among Young Women would respond to vaccination. Widespread vaccination of young women By analyzing the Pfizer-BioNTech vac- against human papillomavirus (HPV) has led cine’sperformanceduringalateJanuaryout- to a greater than 80% reduction in infec- the 4 HPV strains most likely to cause dis- break at 2 Connecticut skilled nursing facili- tions with the 4 strains most often associ- ease. Newer versions that protect against 9 ties, investigators from the CDC and the ated with disease, according to a CDC study. -
Download File (Pdf)
2021 FORUM REPORT COVID-19 in Africa one year on: Impact and Prospects MO IBRAHIM FOUNDATION 2021 FORUM REPORT COVID-19 in Africa one year on: Impact and Prospects MO IBRAHIM FOUNDATION Foreword by Mo Ibrahim Notwithstanding these measures, on current projections Founder and Chair of the Mo Ibrahim Africa might not be adequately covered before 2023. Foundation (MIF) Vaccinating Africa is an urgent matter of global security and all the generous commitments made by Africa’s partners must now be delivered. Looking ahead - and inevitably there will be future pandemics - Africa needs to significantly enhance its Over a year ago, the emergence and the spread of COVID-19 homegrown vaccine manufacturing capacity. shook the world and changed life as we knew it. Planes were Africa’s progress towards its development agendas was off grounded, borders were closed, cities were shut down and course even before COVID-19 hit and recent events have people were told to stay at home. Other regions were hit created new setbacks for human development. With very earlier and harder, but Africa has not been spared from the limited access to remote learning, Africa’s youth missed out pandemic and its impact. on seven months of schooling. Women and girls especially The 2021 Ibrahim Forum Report provides a comprehensive are facing increased vulnerabilities, including rising gender- analysis of this impact from the perspectives of health, based violence. society, politics, and economics. Informed by the latest data, The strong economic and social impacts of the pandemic it sets out the challenges exposed by the pandemic and the are likely to create new triggers for instability and insecurity. -
UNICEF Pentavalent-Hexa 2021+ Pre-Tender Industry Consultation
UNICEF Pentavalent-Hexa 2021+ Pre-Tender Industry Consultation 19th SEPTEMBER 2019 1 Presentation Outline 1. Context ▪ Gavi Board decision ▪ Hexa strategic alignment ▪ Value Based Assessment 2. Demand scenarios and assumptions 3. Pentavalent Tender: ▪ Objectives ▪ Scope ▪ Duration ▪ Modality 4. Summary of feedback and response to questionnaire 5. Timelines 1. CONTEXT Gavi Board decision Hexa strategic alignment Value Based Assessment 3 Gavi Board November 2018 – Decisions IPV Post-2020 DTP booster VIS 2018 VIS 2018 + Hexavalent as immunisation option • Approved support for D, T & P vaccines (Td, DTwP, pentavalent) to be used as booster doses beginning in 2021 • Approved support for inactivated poliovirus vaccine (IPV), with country financing arrangements subject to alignment with the final parameter setting for Gavi 5.0 at the June 2019 Board meeting* • Approved in principle support of wP-Hexavalent vaccine, subject to a vaccine being licenced, recommended for use by WHO, WHO pre-qualified and that market attributes support the successful implementation of Hexavalent The development of capacity for standalone IPV remains the main priority for Gavi Alliance as part of the effort to eradicate polio All Gavi Board decisions are “subject to the availability of funding for the 2021-2025 period and alignment with the final parameter setting for Gavi 5.0 at the June 2019 Board meeting.” *Gavi's Board approved IPV co-financing arrangements post-2020 in its June 2019 session 4 Conditions to open a funding window for Hexavalent Condition 1: Hexavalent vaccines that are candidates for Gavi support should achieve IPV immunogenicity targets as per WHO’s SAGE recommendations. Condition 2: Hexavalent vaccines are priced in line with value-based principles. -
HPV – Facts About the Virus, the Vaccine and What This Means For
The WHO Regional The World Health Organization (WHO) is a specialized agency of the United Nations created in 1948 with the primary responsibility for international health matters each with its own programme geared to the particular health conditions of the countries it serves. Member States Albania Andorra Armenia Austria Azerbaijan Belarus Belgium Bosnia and Herzegovina Bulgaria Croatia Cyprus Czechia HPV – facts about the virus, Denmark Estonia Finland France the vaccine and what this Georgia Germany Greece means for you Hungary Iceland Ireland Israel Italy Kazakhstan Kyrgyzstan Answers to common questions Latvia Lithuania asked by adolescents and Luxembourg Malta young adults Monaco Montenegro Netherlands Norway Poland Portugal Republic of Moldova Romania Russian Federation San Marino Serbia Slovakia Slovenia Spain Sweden Switzerland Tajikistan The former Yugoslav Republic of Macedonia Turkey Turkmenistan Ukraine United Kingdom UN City, Marmorvej 51, DK-2100 Copenhagen Ø, Denmark Uzbekistan Tel.: +45 45 33 70 00 Fax: +45 45 33 70 01 E-mail: [email protected] Q&A: Answers to common questions asked by adolescents and young adults HPV and vaccination HPV stands for human papillomavirus. There are over What is HPV and why should I be vaccinated 200 known types of the virus, 30 of which are transmitted against it? through sexual activity. HPV is the most common sexually transmitted infection in the world. Almost 80% of sexually active people will get infected with one or more HPV types in their lifetime. HPV infection can lead to several types of cancer and genital warts. Cervical cancer is the most common type of cancer caused by HPV, and it is the fourth most common cancer in women worldwide. -
Case Studies Controversies in Vaccination
European Review, Vol. 21, No. S1, S56–S61 r 2013 Academia Europæa. The online version of this article is published within an Open Access environment subject to the conditions of the Creative Commons Attribution license ,http://creativecommons.org/licenses/by/3.0/.. doi:10.1017/S1062798713000227 Session 3 – Case Studies Controversies in Vaccination ROMAN PRYMULA University Hospital Hradec Kralove, Sokolska 581, 500 05 Hradec Kralove, Czech Republic. E-mail: [email protected] Infectious diseases still jeopardize human health and even lives. In spite of the variety of advanced treatment methods, prevention is considered to be the most effective way to fight infections, and vaccination, no doubt, is one of the most effective preventive measures in the history of mankind. The vaccine controversy is based on a dispute over morality, ethics, effectiveness, and/or safety. There is no 100% safe or effective vaccine; however, benefits clearly overweigh risks. Ironically, as the numbers of cases of vaccine- preventable infectious diseases are falling, the controversies relating to vaccine safety are growing. Vaccines are generally victims of their own success. Controversies can afflict the positive acceptance of immunization, decrease the coverage and uptake and finally threaten the health of children and adults. The advent of vaccination has proven to be one of the most effective preventive measures in the history of medicine. Vaccines play a significant role in the prevention of debili- tating and, in many cases, life-threatening infectious diseases. Vaccines also provide important benefits in terms of reducing or avoiding costs associated with illness, both direct and indirect. In spite of the absence of any kind of ideal global healthcare system and lack of resources, the World Health Organisation (WHO) and the United Nations Children’s Fund (UNICEF) were able, in 1974, to establish a major global project called the Expanded Programme on Immunization (EPI). -
Considerations for Causality Assessment of Neurological And
Occasional essay J Neurol Neurosurg Psychiatry: first published as 10.1136/jnnp-2021-326924 on 6 August 2021. Downloaded from Considerations for causality assessment of neurological and neuropsychiatric complications of SARS- CoV-2 vaccines: from cerebral venous sinus thrombosis to functional neurological disorder Matt Butler ,1 Arina Tamborska,2,3 Greta K Wood,2,3 Mark Ellul,4 Rhys H Thomas,5,6 Ian Galea ,7 Sarah Pett,8 Bhagteshwar Singh,3 Tom Solomon,4 Thomas Arthur Pollak,9 Benedict D Michael,2,3 Timothy R Nicholson10 For numbered affiliations see INTRODUCTION More severe potential adverse effects in the open- end of article. The scientific community rapidly responded to label phase of vaccine roll- outs are being collected the COVID-19 pandemic by developing novel through national surveillance systems. In the USA, Correspondence to SARS- CoV-2 vaccines (table 1). As of early June Dr Timothy R Nicholson, King’s roughly 372 adverse events have been reported per College London, London WC2R 2021, an estimated 2 billion doses have been million doses, which is a lower rate than expected 1 2LS, UK; timothy. nicholson@ administered worldwide. Neurological adverse based on the clinical trials.6 kcl. ac. uk events following immunisation (AEFI), such as In the UK, adverse events are reported via the cerebral venous sinus thrombosis and demyelin- MB and AT are joint first Coronavirus Yellow Card reporting website. As of ating episodes, have been reported. In some coun- authors. early June 2021, approximately 250 000 Yellow tries, these have led to the temporary halting of BDM and TRN are joint senior Cards have been submitted, equating to around authors. -
Immunogenicity and Safety of a Fully Liquid Dtap-IPV-Hep B-PRP-T
ccines & a V f V a o c l c i a n n a Lanata et al., J Vaccines Vaccin 2012, 3:1 r t u i o o n J Journal of Vaccines & Vaccination DOI: 10.4172/2157-7560.1000128 ISSN: 2157-7560 Research Article Open Access Immunogenicity and Safety of a Fully Liquid DTaP-IPV-Hep B-PRP-T Vaccine at 2-4-6 Months of Age in Peru Claudio Lanata1, Betzana Zambrano2, Lucie Ecker1, Isabel Amemiya1, Ana Gil1 and Eduardo Santos Lima3* 1Instituto de Investigación Nutricional, Lima, Peru 2Sanofi Pasteur, Montevideo, Uruguay 3Clinical Development, Sanofi Pasteur, Lyon, France Abstract Objectives: To assess the immunogenicity and safety of a new candidate, fully liquid, hexavalent DTaP-IPV- Hep B-PRP-T vaccine (Hexaxim™, an AcXim family vaccine) compared to a licensed hexavalent DTaP-IPV-Hep B// PRP-T vaccine (Infanrix hexa®) in Peru. Methods: Infants born to HBsAg seronegative mothers and who had not received a hepatitis B vaccine prior to entry into the study were randomized to receive either Hexaxim™ (Group 1) or Infanrix hexa® (Group 2) at 2, 4, 6 months of age. Seroprotection (SP) rate for hepatitis B (anti-HBs antibody concentration ≥10 mIU/mL) was analysed for non-inferiority (Group 1 minus Group 2) 1 month post-primary series. Anti-diphtheria and anti-polyrosil ribitol phosphate (PRP) antibody responses were analysed descriptively. Safety was analysed from parental reports. Results: Seroprotection rate for anti-HBs antibody titers ≥10 mIU/mL was high in both groups (≥99.2%) and non-inferiority was demonstrated (lower bound of the 95% CI for the difference was -4.17, above the pre-defined delta [-10%]). -
Supplemental Information and Guidance for Vaccination Providers Regarding Use of 9-Valent HPV Vaccine
Supplemental information and guidance for vaccination providers regarding use of 9-valent HPV A 9-valent human papillomavirus (HPV) vaccine (9vHPV, Gardasil 9, Merck & Co.) was licensed for use in females and males in December 2014.1,2,3,4 The 9vHPV was the third HPV vaccine licensed in the United States by the Food and Drug Administration (FDA); the other vaccines are bivalent HPV vaccine (2vHPV, Cervarix, GlaxoSmithKline), licensed for use in females, and quadrivalent HPV vaccine (4vHPV, Gardasil, Merck & Co.), licensed for use in females and males.5 In February 2015, the Advisory Committee on Immunization Practices (ACIP) recommended 9vHPV as one of three HPV vaccines that can be used for routine vaccination of females and one of two HPV vaccines for routine vaccination of males.6 After the end of 2016, only 9vHPV will be distributed in the United States. In October 2016, ACIP updated HPV vaccination recommendations regarding dosing schedules.7 CDC now recommends two doses of HPV vaccine (0, 6–12 month schedule) for persons starting the vaccination series before the 15th birthday. Three doses of HPV vaccine (0, 1–2, 6 month schedule) continue to be recommended for persons starting the vaccination series on or after the 15th birthday and for persons with certain immunocompromising conditions. Guidance is needed for persons who started the series with 2vHPV or 4vHPV and may be completing the series with 9vHPV. The information below summarizes some of the recommendations included in ACIP Policy Notes and provides additional guidance.5-7 Information about the vaccines What are some of the similarities and differences between the three HPV vaccines? y Each of the three HPV vaccines is a noninfectious, virus-like particle (VLP) vaccine. -
Human Papillomavirus Vaccine
Human Papillomavirus Vaccine: Supply and Demand Update UNICEF Supply Division October 2020 0 Human Papillomavirus Vaccine Supply and Demand Update - October 2020 This update provides information on human papillomavirus vaccine, including supply, demand, and pricing trends. It highlights continued supply constraints foreseen over 2020 and 2021, which also affects countries procuring through UNICEF. UNICEF requests self-financing middle-income countries to consolidate credible multi-year demand and to submit multi-year commitments through UNICEF. 1. Summary • UNICEF’s strategic plan for 2018-2021 seeks to ensure that at least 24 countries nationally introduce human papillomavirus (HPV) vaccine into their immunization programmes.1 As of to date, 20 countries supplied through UNICEF, of which 15 supported by Gavi, the Vaccine Alliance (Gavi) and five countries having transitioned from Gavi support and self-finance their procurement, have introduced HPV vaccines since 2013. Fourteen middle-income countries (MICs) are also procuring HPV vaccines through UNICEF. From 2013 to 2019, UNICEF’s total HPV vaccine procurement reached 30.9 million doses in support of girls. There is currently no gender-neutral programmes in countries supplied through UNICEF. Of the 30.9 million doses, UNICEF procured 28.3 million doses (91 per cent) for countries supported by Gavi, including those that transitioned from Gavi support and still access Gavi prices, and 2.6 million doses (9 per cent) on behalf of self-financing MICs. • In December 2016, Gavi revised its programme strategy to support full-scale national HPV vaccine introductions with multi-age cohort (MAC) vaccinations. This substantially increased HPV vaccine demand through UNICEF from 2017. -
Vaccinations for Preteens and Teens, Age 11-19 Years
Vaccinations for Preteens and Teens, Age 11–19 Years Getting immunized is a lifelong, life-protecting job. Make sure you and your healthcare provider keep your immunizations up to date. Check to be sure you’ve had all the vaccinations you need. Vaccine Do you need it? Chickenpox Yes! If you haven’t been vaccinated and haven’t had chickenpox, you need 2 doses of this vaccine. (varicella; Var) Anybody who was vaccinated with only 1 dose should get a second dose. Hepatitis A Yes! If you haven’t been vaccinated, you need 2 doses of this vaccine. Anybody who was vaccinated (HepA) with only 1 dose should get a second dose at least 6–18 months later. Hepatitis B Yes! This vaccine is recommended for all people age 0–18 years. You need a hepatitis B vaccine series (HepB) if you have not already received it. Haemophilus influ- Maybe. If you haven’t been vaccinated against Hib and have a high-risk condition (such as a non- enzae type b (Hib) functioning spleen), you need this vaccine. Human Yes! All preteens need 2 doses of HPV vaccine at age 11 or 12. Older teens who haven't been vacci- papillomavirus nated will need 2 or 3 doses. This vaccine protects against HPV, a common cause of genital warts and (HPV) several types of cancer, including cervical cancer and cancer of the anus, penis, and throat. Influenza Yes! Everyone age 6 months and older needs annual influenza vaccination every fall or winter and (Flu) for the rest of their lives. -
(Nitags) and WHO Immunisation-Related Advisory Committees
Summary of recent issues considered by four national immunisation technical advisory groups (NITAGs) and WHO immunisation-related advisory committees Prepared by the National Centre for Immunisation Research & Surveillance (NCIRS) Period of review: 16/05/2019 to 13/09/2019 Contents 1 Advisory Committee on Immunization Practices (ACIP), USA .......................................................... 3 1.1 ACIP meeting: 26-27 June 2019 ....................................................................................................... 3 1.2 Newly published or updated recommendations ............................................................................... 20 1.2.1 Japanese Encephalitis Vaccine: Recommendations of the Advisory Committee on Immunisation Practices.......................................................................................................................... 20 1.2.2 Human Papillomavirus Vaccination for Adults: Updated Recommendations of the Advisory Committee on Immunization Practice ..................................................................................................... 20 1.2.3 Prevention and Control of Seasonal Influenza with Vaccines: Recommendations of the Advisory Committee on Immunization Practices — United States, 2019–20 Influenza Season ............ 21 1.3 New or updated recommendations – not yet published ................................................................... 21 2 Immunisation Advisory Centre (IMAC), New Zealand ....................................................................